These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28590458)

  • 1. Highlights in myeloproliferative neoplasms from the 2016 American Society of Hematology meeting: Commentary.
    Mesa RA
    Clin Adv Hematol Oncol; 2017 Feb; 15 Suppl 2(2):21-23. PubMed ID: 28590458
    [No Abstract]   [Full Text] [Related]  

  • 2. Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting: commentary.
    Mesa RA
    Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 2(1):18-19. PubMed ID: 31545310
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myeloproliferative neoplasms].
    Komatsu N
    Rinsho Ketsueki; 2013 Jan; 54(1):71-8. PubMed ID: 23391649
    [No Abstract]   [Full Text] [Related]  

  • 4. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Therapeutic Strategy for Myeloproliferative Neoplasms].
    Nagata K; Shimoda K
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1918-23. PubMed ID: 30160899
    [No Abstract]   [Full Text] [Related]  

  • 5. Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.
    Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 2(1):1-20. PubMed ID: 31545309
    [No Abstract]   [Full Text] [Related]  

  • 6. [Transient myeloproliferative disorder in Down syndrome].
    Ito E; Toki T
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():687-91. PubMed ID: 23134029
    [No Abstract]   [Full Text] [Related]  

  • 7. American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
    Walker K
    IDrugs; 2007 Feb; 10(2):78-80. PubMed ID: 17285452
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloproliferative Disorders.
    Meier B; Burton JH
    Hematol Oncol Clin North Am; 2017 Dec; 31(6):1029-1044. PubMed ID: 29078922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative disorders.
    Meier B; Burton JH
    Emerg Med Clin North Am; 2014 Aug; 32(3):597-612. PubMed ID: 25060252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.
    Khan M; Sarfraz M; Daver N
    Future Oncol; 2017 Jan; 13(2):117-120. PubMed ID: 27676208
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of inchinkoto for a patient with liver fibrosis complicated with transient abnormal myelopoiesis in Down's syndrome.
    Takeyama M; Uchida Y; Arai I; Kamamoto T; Nishikubo T; Kanehiro H; Sado T; Kunishima S; Takahashi Y
    Pediatr Int; 2011 Dec; 53(6):1093-6. PubMed ID: 22181572
    [No Abstract]   [Full Text] [Related]  

  • 12. [The cutting edge of medicine: pathophysiology and treatment of myeloproliferative neoplasms].
    Komatsu N
    Nihon Naika Gakkai Zasshi; 2014 Feb; 103(2):440-9. PubMed ID: 24724385
    [No Abstract]   [Full Text] [Related]  

  • 13. [Myeloproliferative disorders: the molecular era].
    Varet B
    Rev Prat; 2005 Oct; 55(15):1639-41. PubMed ID: 16334199
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity.
    Palandri F; Labate C; Sabattini E; Catani L; Martino B
    Am J Hematol; 2016 Aug; 91(8):E329-30. PubMed ID: 27145026
    [No Abstract]   [Full Text] [Related]  

  • 15. Preface.
    Verstovsek S
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):81-2. PubMed ID: 25189719
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction to 'Spotlight on myeloproliferative neoplasms'.
    Muller-Berat Killmann CN
    Leukemia; 2008 Jan; 22(1):2. PubMed ID: 18197172
    [No Abstract]   [Full Text] [Related]  

  • 17. Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.
    Lasky J; Sakamoto KM
    MedGenMed; 2005 Mar; 7(1):21. PubMed ID: 16369326
    [No Abstract]   [Full Text] [Related]  

  • 18. New perspectives in managing myeloproliferative disorders: focus on the patient.
    Birgegård G
    Hematol Oncol; 2009 Jun; 27 Suppl 1():5-7. PubMed ID: 19468983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myeloproliferative disorders.
    Campbell PJ; Green AR
    N Engl J Med; 2006 Dec; 355(23):2452-66. PubMed ID: 17151367
    [No Abstract]   [Full Text] [Related]  

  • 20. [Reduction of Ph1 chromosome in atypical myeloproliferative disorder by intensive chemotherapy].
    Takeyama H; Yano K; Fukutani H; Yamamoto F; Watanabe E; Satake T
    Rinsho Ketsueki; 1986 Sep; 27(9):1640-4. PubMed ID: 3468279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.